Treating malignant melanoma when a rare BRAF V600M mutation is present: case report and literature review

1. CHENG Y, ZHANG G, LI G. Targeting MAPK pathway in melanoma therapy. Cancer Metastasis Rev. 2013; 32(3–4):567-84.10.1007/s10555-013-9433-9Search in Google Scholar

2. DAVIES H, BIGNELL GR, COX C, STEPHENS P, EDKINS S, CLEGG S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002; 417(6892):949-54.10.1038/nature00766Search in Google Scholar

3. MALDONADO JL, FRIDLYAND J, PATEL H, JAIN AN, BUSAM K, KAGESHITA T, et al. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst. 2003; 95(24):1878-90.10.1093/jnci/djg123Search in Google Scholar

4. VOSKOBOYNIK M, MAR V, MAILER S, et al. Clinico-pathological characteristics associated with BRAF(K) (601E) and BRAF(L) (597) mutations in melanoma. Pigment Cell Melanoma Res. 2016; 29 (2):222-8.10.1111/pcmr.12450Search in Google Scholar

5. CHAPMAN PB, HAUSCHILD A, ROBERT C, HAANEN JB, ASCIERTO P, LARKIN J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364(26):2507-16.10.1056/NEJMoa1103782Search in Google Scholar

6. MCARTHUR GA, CHAPMAN PB, ROBERT C, et al. Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. The Lancet Oncology. 2014; 15(3):323-332.10.1016/S1470-2045(14)70012-9Open DOISearch in Google Scholar

7. HAUSCHILD A, GROB JJ, DEMIDOV LV, JOUARY T, GUTZMER R, MILLWARD M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012; 380(9839):358-65.10.1016/S0140-6736(12)60868-XSearch in Google Scholar

8. LARKIN J, ASCIERTO PA, DRENO B, et al. Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma. N Engl J Med. 2014; 371:1867.10.1056/NEJMoa1408868Search in Google Scholar

9. LONG GV, STROYAKOVSKIY D, GOGAS H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 2015; 386(9992):444-51.10.1016/S0140-6736(15)60898-4Search in Google Scholar

10. ROBERT C, KARASZEWSKA B, SCHACHTER J, et al. Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib. N Engl J Med 2015; 372:30-3910.1056/NEJMoa1412690Search in Google Scholar

11. PARAKH S, MURPHY C, LAU D, CEBON JS, ANDREWS MC. Response to MAPK pathway inhibitors in BRAF V600Mmutated metastatic melanoma. J Clin Pharm Ther. 2015; 40(1):121-3.10.1111/jcpt.12229Search in Google Scholar

12. PONTI G, TOMASI A, PELLACANI G. Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma. J Hematol Oncol. 2012; 5:60.10.1186/1756-8722-5-60Search in Google Scholar